BridgeMD
New treatment option for Respiratory Infections in Children
Official title Trial of an AI-enabled Digital Stethoscope to Improve Antibiotic Stewardship
ClinicalTrials.gov ID: NCT07362433
What this study is testing
- What it's testing
- Antibiotics are a mainstay of the treatment of lower respiratory infections in young children even though most episodes are caused by self-limiting viruses. Innovative child friendly tools that improve the diagnosis of respiratory illnesses, safely reduce the unnecessary use of antibiotics, and are suitable for implementation in resource-constrained settings are urgently required to safely improve antibiotic stewardship and stem the rising rates of antibiotic resistance globally.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 to 59
You may be able to join if
- 2 to 59 months of age (60 days to 59 months 29 days),
- illness duration 14 days or less,
- meeting non-severe pneumonia criteria, and
- from the trial catchment areas.
You likely can't join if
- prior participation,
- age \ 59 months,
- illness duration \>14 days,
- not meeting IMCI-defined non-severe pneumonia criteria,
- oxygen saturation (SpO2) \<90%,
- moderate or severe malnutrition,
See the full eligibility criteria
- 2 to 59 months of age (60 days to 59 months 29 days),
- illness duration 14 days or less,
- meeting non-severe pneumonia criteria, and
- from the trial catchment areas.
- prior participation,
- age \ 59 months,
- illness duration \>14 days,
- not meeting IMCI-defined non-severe pneumonia criteria,
- oxygen saturation (SpO2) \<90%,
- moderate or severe malnutrition,
- known chronic disease,
- history of prematurity,
- one or more high risk clinical signs (any WHO-defined clinical danger sign and/or WHO-defined emergency sign),
- known antibiotic exposure in the past 1 week,
- non-respiratory illness requiring systemic antibiotic treatment according to IMCI guidelines.
The study team makes the final eligibility decision.
Where it's taking place
- Sylhet, Bangladesh
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 months to 59 months. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sylhet, Bangladesh. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.